Mpox Resource Center

The National Coalition for LGBTQ Health’s Mpox Resource Center provides information, data, links to resources, and general news from multiple sources on mpox in the United States on topics including prevention, transmission, testing, and treatment.

Resources from the CDC

It’s not clear how people were exposed to mpox, but early data suggest that gay, bisexual, and other men who have sex with men make up a high number of cases. However, anyone who has been in close contact with someone who has mpox is at risk. CDC is urging healthcare providers in the U.S. to be alert for patients who have rash illnesses consistent with mpox, regardless of whether they have travel or specific risk factors for mpox and regardless of gender or sexual orientation.

CDC is working with state and local health officials to identify people who may have been in contact with individuals who have tested positive for mpox, so they can monitor their health.

Stay current on CDC’s mpox resources online by visiting the What’s New & Updated page.

Latest Updates

NIH: Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen
Study highlights need for defined markers of mpox immunity to inform public health use.

Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS® by establishing additional pathways for vaccine procurement, distribution, and reimbursement by both public and private payers.

Evidence-based interventions are needed to respond to current and future mpox outbreaks within and beyond the United States. To help meet domestic and international mpox response goals, CDC is urging clinicians to let patients with mpox know that oral tecovirimat is available through STOMP and encourage them to enroll. Providers should inform patients about STOMP so they can consider enrolling in the study. However, enrollment in the study is voluntary, and patients who decline to take part, or who do not meet the criteria to participate, can still obtain tecovirimat if recommended. For more information about obtaining TPOXX or about the STOMP study, visit or   

Information for Healthcare Providers: Tecovirimat (TPOXX) and Guidance for Tecovirimat Use pages are now live.

Mpox Vaccination Basics

Treatment Information for Healthcare Professionals

If You Are Sick
Funding Resources
Health Departments

FAQ videos from Kaiser Family Foundation, rights-free and designed for sharing

Resources from Greater Than AIDS

Mpox Resources from Greater Than HIV
Demetre Daskalakis, MD, MPH, Acting Director of the National Center for Immunization and Respiratory Diseases at the CDC, provides the latest on mpox in this FAQ series from KFF and CDC.

Copyright © 2024 National Coalition for LGBTQ Health | All rights reserved.